Opinion|Videos|January 28, 2025
Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
Author(s)Jeffrey V. Matous, MD
Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the primary barriers preventing widespread use of bispecific antibody therapies in community practices, and what innovative solutions or models of care could help address these challenges?
- Several ASH 2024 abstracts highlighted community center experiences with bispecific antibody therapies. What insights from these studies stand out to you, and how can they guide broader adoption of these therapies in the community setting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust
3
New Dermatologic Therapies Make Waves at Maui Derm 2026
4
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
5
